Toviaz is a brand name of fesoterodine, approved by the FDA in the following formulation(s):
TOVIAZ (fesoterodine fumarate - tablet, extended release; oral)
Manufacturer: PFIZER
Approval date: October 31, 2008
Strength(s): 4MG, 8MG [RLD]
Has a generic version of Toviaz been approved?
No. There is currently no therapeutically equivalent version of Toviaz available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Toviaz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Stable salts of novel derivatives of 3,3-diphenylpropylamines
Patent 6,858,650
Issued: February 22, 2005
Inventor(s): Meese; Claus
Assignee(s): Schwarz Pharma AG
The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(−)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.Patent expiration dates:
- May 11, 2019✓✓
- May 11, 2019
Derivatives of 3,3-diphenylpropylamines
Patent 7,384,980
Issued: June 10, 2008
Inventor(s): Meese; Claus & Sparf; Bengt
Assignee(s): Schwarz Pharma AG
The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Patent expiration dates:
- May 11, 2019✓✓✓
- May 11, 2019
Pharmaceutical compositions comprising fesoterodine
Patent 7,807,715
Issued: October 5, 2010
Inventor(s): Arth; Christoph & Komenda; Michael & Bicane; Fatima & Mika; Hans-Jurgen
Assignee(s): UCB Pharma GmbH
The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Patent expiration dates:
- June 7, 2027✓✓
- June 7, 2027
Derivatives of 3,3-diphenylpropylamines
Patent 7,855,230
Issued: December 21, 2010
Inventor(s): Meese; Claus & Sparf; Bengt
Assignee(s): UCB Pharma GmbH
The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Patent expiration dates:
- May 11, 2019✓
- May 11, 2019
Derivatives of 3,3-diphenylpropylamines
Patent 7,985,772
Issued: July 26, 2011
Inventor(s): Meese; Claus & Sparf; Bengt
Assignee(s): UCB Pharma GmbH
The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Patent expiration dates:
- May 11, 2019✓✓✓
- May 11, 2019
Pharmaceutical compositions comprising fesoterodine
Patent 8,088,398
Issued: January 3, 2012
Inventor(s): Mika; Hans-Jürgen & Arth; Christoph & Komenda; Michael & Bicane; Fatima
Assignee(s): UCB Pharma GmbH
The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Patent expiration dates:
- June 7, 2027✓✓
- June 7, 2027
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 31, 2013 - NEW CHEMICAL ENTITY
See also...
- Toviaz Consumer Information (Drugs.com)
- Toviaz Consumer Information (Wolters Kluwer)
- Toviaz Consumer Information (Cerner Multum)
- Toviaz Advanced Consumer Information (Micromedex)
- Toviaz AHFS DI Monographs (ASHP)
- Fesoterodine Consumer Information (Wolters Kluwer)
- Fesoterodine Consumer Information (Cerner Multum)
- Fesoterodine Advanced Consumer Information (Micromedex)
- Fesoterodine Fumarate AHFS DI Monographs (ASHP)
No comments:
Post a Comment